RT Journal Article
SR Electronic
T1 Accuracy of computer-aided chest X-ray screening in the Kenya National Tuberculosis Prevalence Survey
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.21.21265321
DO 10.1101/2021.10.21.21265321
A1 Brenda Mungai
A1 Jane Ong‘angò
A1 Chu Chang Ku
A1 Marc YR Henrion
A1 Ben Morton
A1 Elizabeth Joekes
A1 Elizabeth Onyango
A1 Richard Kiplimo
A1 Dickson Kirathe
A1 Enos Masini
A1 Joseph Sitienei
A1 Veronica Manduku
A1 Beatrice Mugi
A1 The IMPALA Consortium
A1 Stephen Bertel Squire
A1 Peter MacPherson
YR 2021
UL http://medrxiv.org/content/early/2021/10/30/2021.10.21.21265321.abstract
AB Background Community-based screening for tuberculosis (TB) could improve detection but is resource intensive. We set out to evaluate the accuracy of computer-aided TB screening using digital chest X-ray (CXR) to determine if this approach met target product profiles (TPP) for community-based screening.Methods CXR images from participants in the 2016 Kenya National TB Prevalence Survey were evaluated using CAD4TBv6 (Delft Imaging), giving a probabilistic score for pulmonary TB ranging from 0 (low probability) to 99 (high probability). We constructed a Bayesian latent class model to estimate the accuracy of CAD4TBv6 screening compared to bacteriologically-confirmed TB across CAD4TBv6 threshold cut-offs, incorporating data on Clinical Officer CXR interpretation, participant demographics (age, sex, TB symptoms, previous TB history), and sputum results. We compared model-estimated sensitivity and specificity of CAD4TBv6 to optimum and minimum TPPs.Results Of 63,050 prevalence survey participants, 61,848 (98%) had analysable CXR images, and 8,966 (14.5%) underwent sputum bacteriological testing; 298 had bacteriologically-confirmed pulmonary TB. Median CAD4TBv6 scores for participants with bacteriologically-confirmed TB were significantly higher (72, IQR: 58-82.75) compared to participants with bacteriologically-negative sputum results (49, IQR: 44-57, p<0.0001). CAD4TBv6 met the optimum TPP; with the threshold set to achieve a mean sensitivity of 95% (optimum TPP), specificity was 83.3%, (95% credible interval [CrI]: 83.0%—83.7%, CAD4TBv6 threshold: 55). There was considerable variation in accuracy by participant characteristics, with older individuals and those with previous TB having lowest specificity.Conclusions CAD4TBv6 met the optimal TPP for TB community screening. To optimise screening accuracy and efficiency of confirmatory sputum testing, we recommend that an adaptive approach to threshold setting is adopted based on participant characteristics.Take home message CAD4TBv6 met the optimal WHO target product profile for a community TB screening tool. Specificity was lower in adults with previous TB and those aged 41 years or older; an adaptive approach to setting CAD thresholds will likely be required to optimize use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the National Institute for Health Research (NIHR) (IMPALA, grant reference 16/136/35) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. PM is funded by Wellcome (200901/Z/16/Z). MYRH was in part supported by a strategic award from Wellcome to Malawi-Liverpool-Wellcome Trust Clinical Research programme (206545/Z/17/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted as part of the Kenya Prevalence survey ethics approval reference number SSC 2094 by the Kenya Medical Research Institute.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Kenya National Tuberculosis, Leprosy and Lung Disease program is the custodian of the 2016 Kenya Tuberculosis Prevalence Survey data.